|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Authorisation of IMP Destruction** | | | | | | | | | | | | | | | |
| **Study title:** SepTiC (Sepsis Trials in Critical Care)  **Sponsor:** Imperial College London | | | | | | | | **Chief Investigator:**  Prof Anthony Gordon | | | | | | | |
| **Protocol number:** 22SM8039 | | | **IMP name, form and strength:** Sargramostim 250μg/vial | | | | | | | | | | | | |
| **Site Name/Number:** | | | **Principal Investigator:** | | | | | | | | | | | | |
|  |  |  |  |  |  |  | | |  | |  |  |  |  | | |
| **IMP kit code**  (list all IMP kit codes – one per row) | | **Batch number** | **Expiry date** | | | | **Quantity to be destroyed** | **(Used/**  **unused)** | | **Comments** | | | | |
|  | |  |  | | | |  |  | |  | | | | |
|  | |  |  | | | |  |  | |  | | | | |
|  | |  |  | | | |  |  | |  | | | | |
|  | |  |  | | | |  |  | |  | | | | |
|  | |  |  | | | |  |  | |  | | | | |
|  | |  |  | | | |  |  | |  | | | | |
|  | |  |  | | | |  |  | |  | | | | |
|  | |  |  | | | |  |  | |  | | | | |
|  | |  |  | | | |  |  | |  | | | | |
|  | |  |  | | | |  |  | |  | | | | |
|  | |  |  | | | |  |  | |  | | | | |
|  | |  |  | | | |  |  | |  | | | | |
| **The Investigational Medicinal Product (IMP) will be/has been destroyed in accordance with the applicable institutional and legal regulations and according to GMP/GCP guidelines.** | | | | | | | | | | | | | | | |
| Method of destruction: | | | | | | | | | | | | | | | |
| **Destruction authorised by** | | | | | | | | | | | | | | | |
| Trial monitor/Manager name: | | | Signature. | | | | | Date | | | | | | | |
| **Destruction completed by** | | | | | | | | | | | | | | | |
| Pharmacy staff name: | | | Signature | | | | | Date | | | | | | | |